Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival - PubMed (original) (raw)

Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival

Stephanie Cham et al. Gynecol Oncol. 2021 Jul.

Abstract

Background: Fragmentation occurs when a patient receives care at more than one hospital, and the long-term effects in ovarian cancer are unknown. We examined the association between fragmentation of primary debulking surgery (PDS) and adjuvant chemotherapy (AC) and overall survival (OS).

Methods: The National Cancer Database was used to identify women with stage II-IV epithelial ovarian cancer between 2004 and 2016 who underwent PDS followed by AC. Fragmentation was defined as receipt of AC at a different institution than where PDS was performed. After propensity score weighting, proportional hazard models were developed to estimate the association between fragmented care and OS.

Results: Of the 36,300 patients identified, 13,347 (36.8%) had fragmented care. Patient factors associated with fragmentation included older age, higher income, and longer travel distance for PDS; hospital factors included PDS performed at a community center or a facility with lower annual surgical volume (P < 0.05, all). Fragmentation was associated with a 15% risk of 30-day delay to AC (aRR 1.15, 95% CI 1.09-1.22). In a propensity scoring weighted analysis, mortality was reduced when AC was fragmented (HR 0.95, 95% CI 0.92-0.97). Sensitivity analyses indicated fragmentation was associated with improved survival in metropolitan residents. Stratified analyses indicated patients who traveled 50 miles or more with PDS and AC at the same institution had the worst OS.

Conclusion: Fragmentation of PDS and AC has no adverse effects on long-term survival. Survival outcomes were worst for those who received care at the same institution 50 miles or more away.

Keywords: Adjuvant chemotherapy; Debulking; Fragmentation; Outcomes research; Ovarian cancer.

Copyright © 2021. Published by Elsevier Inc.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Wright has served as a consultant for Clovis Oncology, received royalties from UpToDate and received research funding from Merck. Dr. Tergas received personal fees from Immunomic Therapeutics. Dr. Hou has served as a consultant for Foundation Medicine. No other authors have any conflicts of interest or disclosures.

MeSH terms

LinkOut - more resources